[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity-morbid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity-morbid":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,73,0,25,[9,52,85,111,140,177,203,231,257,284,307,331,358,378,413,439,464,485,516,538,560,581,607,632,647],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100531527","trans-nasal-endoscopy-for-bariatric-patients-100531527",false,"NCT06200961","Trans-nasal Endoscopy for Bariatric Patients","Use of Sedation-Free Transnasal Endoscopy to Improve Access and Lower Costs of Endoscopic Evaluations in a Bariatric Medical and Surgical Program","TNE","Inclusion Criteria:\n\n1. Patient 18 years of age and less than 90 years of age with clinically referred for esophagoscopy, gastroscopy, or esophagogastroduodenoscopy (EGD)\n2. Cared for in metabolic and bariatric clinic\n\nExclusion Criteria:\n\n1. Patient \\\u003C18 years of age\n2. Medically contraindicated to perform EGD or TNE\n3. Inability to provide informed consent","ALL","18 Years","90 Years",{"count":22,"type":23},100,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study plans to learn if the EvoEndo Endoscopy system can be used to evaluate, provide and follow up care for upper gastrointestinal tract diseases in the bariatric population. The smallest current scope available for such a technique is an adult transnasal endoscope with a larger diameter, a pulmonary bronchoscope or Ear Nose and Throat (ENT) laryngoscope. This study is evaluating a newly Food and Drug Administration (FDA) cleared ultra-slim, single-use, endoscope specifically designed for transnasal endoscopy to evaluate its use in adult upper tract gastrointestinal diseases. If such a technique is successful it could improve the safety, cost, and access of endoscopic care for patients in need of an endoscopic evaluation for a bariatric medical condition.",[29,30,31,32,33],"Obesity","Obesity, Morbid","Obese","GI Disorders","Gastrointestinal Diseases",[35,36,37,38],"Transnasal Endoscopy (TNE)","Esophagogastroduodenoscopy (EGD)","Upper Endoscopy","Endoscopy","RECRUITING","2026-06-23",{"date":42,"type":43},"2026-06-25","ACTUAL",{"date":45,"type":43},"2026-04-20",{"date":47,"type":23},"2028-06",{"name":49,"class":50},"Christopher C. Thompson, MD, MSc","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":24,"phases":62,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":51},"100232937","obesity-cohort--medical-follow-up-of-severe-or-morbid-obese-patients-undergoing-bariatric-surgery-100232937","NCT02310178","Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery","BAREVAL","Inclusion Criteria:\n\n* Only be considered in patients operated and followed at CHU Montpellier with bariatric surgery\n* Patients treated by bariatric surgery on CHU Montpellier\n* Agreed to participate to the study by signing an informed consent\n* Eligible to health insurance\n\nExclusion Criteria:\n\n* Unable to follow the patient in the long term (foreign patients, surgical use ...)\n* Inability to follow in the long run","15 Years",{"count":61,"type":23},750,[26],"The aim of this cohort is to evaluate the follow-up of morbidly obese patients treated by several types of bariatric procedures. In addition, this study could lead to the development of clinical trials on assessment of the bariatric surgery impact.",[30,65],"Bariatric Surgery Candidate",[67,68,69,70,71,72,73,74,75],"weight loss","sleeve gastrectomy","gastric bypass","gastric banding","bariatric procedures","cohort","morbid obesity","medical and economical impact","severe obesity","2026-06-17",{"date":78,"type":43},"2026-06-22",{"date":80,"type":43},"2012-05-21",{"date":82,"type":23},"2028-12",{"name":84,"class":50},"University Hospital, Montpellier",{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":24,"phases":96,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":51},"100602125","low-impact-laparoscopy-in-bariatric-surgery-100602125","NCT07119437","Low Impact Laparoscopy In Bariatric Surgery","Low Impact Laparoscopy In Bariatric Surgery- A Monocentric Randomised Trial Comparing Low-Pressure Pneumoperitoneum Plus Microsurgery Versus Standard Laparoscopy","LILYBET","Inclusion Criteria:\n\n* Age between 18 years-old and 65 years-old\n* BMI (Body Mass Index) \\>35 Kg\u002Fm2 and \\\u003C 45 Kg\u002Fm2;\n* Patients candidate to sleeve gastrectomy\n\nExclusion Criteria:\n\n* Patients with neurological and\u002For psychiatric disorders\n* Patients with Chronic Pain Syndrome\n* Patients with a history of surgical procedures using a laparotomic approach in the upper abdominal quadrants","65 Years",{"count":95,"type":23},128,[26],"The goal of this clinical trial is to learn if low pressure pneumoperitoneum and small incisions (low impact laparoscopy, LIL) works to reduce pain and improve pulmonary function in patients underwent to bariatric surgery.\n\nIt will also learn about the safety and patients' satisfaction of the procedure. The main questions it aims to answer are:\n\nDoes LIL lower post surgical pain and improve pulmonary function? Is LIL safe for obese patients? Researchers will compare LIL to standard laparoscopy performing sleeve gastrectomy in patients with obesity.\n\nParticipants will:\n\nbe randomised to LIL group or standard laparoscopy. After the operation the researchers will evaluate the pain and the efficiency of lung ventilation at pre-established intervals. after 3 months the patients will complete a questionnaire on aesthetic satisfaction and overall satisfaction.",[30],[100,101,68],"obesity","low impact laparoscopy","2026-06-16",{"date":104,"type":43},"2026-06-18",{"date":106,"type":43},"2025-02-04",{"date":108,"type":23},"2026-10-04",{"name":110,"class":50},"Fondazione Policlinico Universitario Campus Bio-Medico",{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":24,"phases":120,"briefSummary":121,"conditions":122,"keywords":129,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":51},"100589244","identification-of-pre-surgical-phenotypic-indicators-predictive-of-quality-of-life-trajectories-in-obese-patients-following-bariatric-surgery-100589244","NCT06951893","Identification of Pre-surgical Phenotypic Indicators Predictive of Quality of Life Trajectories in Obese Patients Following Bariatric Surgery","PHENOBEQOL73","Inclusion Criteria:\n\n* patient \\> 18years old\n* Integrated into the GEROM73 surgical program and starting the intra-hospital program\n\nExclusion Criteria:\n\n* Patients in a state of psychiatric decompensation\n* Patients with cognitive disorders\n* Patients with difficulties understanding the French language, spoken or written\n* Pregnant, parturient, or breastfeeding women",{"count":119,"type":23},165,[26],"This study aims to identify pre-operative phenotypic determinants predictive of quality of life trajectories in post-bariatric surgery patients. In addition, this study will have as a secondary objective the highlighting of a potential link between post-surgery quality of life trajectories and those of anxiety\u002Fdepression scores, eating behaviors and body mass indices.\n\nThis study will be conducted during the usual care of patients undergoing the GEROM73 program, lasting a total of 30 months.\n\nThe GEROM73 program includes care for the six months preceding bariatric surgery and the 24 months following surgery. This program supports patients throughout their bariatric care..\n\nThroughout the GEROM73 program, patients will complete questionnaires on anxiety, depression, eating disorders, Impact of Weight on Quality Of Life.\n\nPatients' weight, body mass index and body schema will also be measured throughout the GEROM program.",[30,123,124,125,126,127,128],"Obesity and Overweight","Bariatric Surgery","Bariatric Surgery Patients","Bariatric Surgery Patient","Bariatric Surgery (Sleeve Gastrectomy )","Bypass, Gastric",[130,116],"GEROM73","2026-06-09",{"date":133,"type":43},"2026-06-10",{"date":135,"type":43},"2025-06-17",{"date":137,"type":23},"2030-09-09",{"name":139,"class":50},"Centre Hospitalier Metropole Savoie",{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":18,"minAge":148,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":153,"conditions":154,"keywords":158,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":51},"100643167","evaluation-of-metabolic-parameters-intestinal-permeability-and-gastrointestinal-symptoms-after-bariatric-surgery-in-body-weight-management-100643167","NCT07643376","Evaluation of Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms After Bariatric Surgery in Body Weight Management","Evaluation of Postoperative Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms in Body Weight Management After Laparoscopic Sleeve Gastrectomy","METABAR","Inclusion Criteria:\n\n* Underwent Laparoscopic Sleeve Gastrectomy (LSG) within the last 1 month\n* Aged between 19-50 years\n* BMI ≥40 kg\u002Fm² or BMI ≥35 kg\u002Fm² with obesity-related comorbidities\n* Signed informed consent form\n* Non-smoker and non-alcohol dependent\n\nExclusion Criteria:\n\n* Did not undergo or is not planned to undergo LSG\n* Outside the age range of 19-50 years\n* Did not sign the informed consent form\n* BMI \\\u003C40 kg\u002Fm² or BMI \\\u003C35 kg\u002Fm² without obesity-related comorbidities\n* Smoker or alcohol dependent\n* Has an inflammatory disease\n* Currently using probiotics, antibiotics, or fiber supplements\n* Has a psychiatric disorder","19 Years","50 Years",{"count":151,"type":23},40,"OBSERVATIONAL","This study aims to evaluate the changes in metabolic parameters, intestinal permeability, and gastrointestinal symptoms in individuals who have undergone bariatric surgery (Laparoscopic Sleeve Gastrectomy - LSG) for obesity treatment.\n\nObesity is a chronic disease associated with serious health complications including type 2 diabetes, hypertension, cardiovascular disease, and metabolic disorders. Bariatric surgery is currently the most effective treatment method for morbid obesity. However, monitoring patients after surgery in terms of metabolic health, gut permeability, and gastrointestinal symptoms is crucial for long-term success.\n\nIn this study, 40 volunteers (aged 19-50) who have undergone LSG surgery within the last month will be followed for 6 months. At the beginning of the study and 6 months later, the following will be assessed:\n\n* Metabolic parameters: fasting blood glucose, total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) cholesterol, and insulin levels\n* Intestinal permeability markers: zonulin, secretory immunoglobulin A (IgA), and lipopolysaccharide (LPS) levels\n* Gastrointestinal symptoms: assessed using the Gastrointestinal Symptom Rating Scale (GSRS)\n* Anthropometric measurements: body weight, height, waist and hip circumference, BMI\n* Nutritional intake: 3-day dietary records\n\nThe study will be conducted at Bursa Yıldırım Doruk Hospital, General Surgery Clinic. Results will contribute to understanding the relationship between bariatric surgery and gut health, potentially helping to prevent postoperative complications.",[30,124,155,156,157],"Intestinal Permeability","Gastrointestinal Symptoms","Metabolic Syndrome",[159,160,161,162,163,164,165,166],"Laparoscopic Sleeve Gastrectomy","Zonulin","Secretory IgA","Lipopolysaccharide","GSRS","Body Weight Management","Gut microbiota","Postoperative Metabolic Parameters","NOT_YET_RECRUITING","2026-06-08",{"date":170,"type":43},"2026-06-11",{"date":172,"type":23},"2026-07-01",{"date":174,"type":23},"2027-02-01",{"name":176,"class":50},"Toros University",{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":51},"100642406","flow-controlled-vs-volume-controlled-ventilation-in-morbidly-obese-patients-undergoing-laparoscopic-bariatric-surgery-100642406","NCT07641829","Flow-Controlled vs Volume-Controlled Ventilation in Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery","Investigation of the Effects of Flow-Controlled Ventilation and Volume-Controlled Ventilation on Pulmonary Dynamics and Hemodynamics in Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery","Inclusion Criteria:\n\n* Age between 18 and 65 years American Society of Anesthesiologists (ASA) physical status I, II, or III Body Mass Index (BMI) ≥ 40 kg\u002Fm² Scheduled for elective laparoscopic bariatric surgery Willing to participate in the study\n\nExclusion Criteria:\n\n* ASA physical status IV or V Emergency surgical procedures Pregnant patients Patients requiring vasopressor support to maintain mean arterial pressure above 65 mmHg intraoperatively Patients with advanced pulmonary disease Patients who decline to participate in the study",{"count":185,"type":23},34,"The goal of this clinical trial is to compare the effects of flow-controlled ventilation (FCV) and volume-controlled ventilation (VCV) on hemodynamic and respiratory parameters in obese patients undergoing elective laparoscopic bariatric surgery. The main questions it aims to answer are:\n\nDoes FCV provide better intraoperative hemodynamic and respiratory stability compared to VCV during laparoscopic bariatric surgery? Is FCV a safe and feasible ventilation strategy under high intraabdominal pressure and position changes required in bariatric surgery?\n\nResearchers will compare FCV group to VCV group to see if FCV improves intraoperative respiratory mechanics and hemodynamic parameters.\n\nParticipants will:\n\nUndergo elective laparoscopic bariatric surgery with BMI \\>40 kg\u002Fm² (ASA I-III) Receive either flow-controlled or volume-controlled ventilation with individualized PEEP and tidal volume of 6-8 ml\u002Fkg predicted body weight Have intraoperative hemodynamic and respiratory parameters monitored at regular intervals, including arterial blood gas analysis Be followed postoperatively for oxygen therapy requirement and intensive care need",[30,127,188],"Mechanical Ventilation",[190,191,192,193,194],"Flow-controlled ventilation","Volume-controlled ventilation","Respiratory mechanics","Lung-protective ventilation","Bariatric surgery","2026-06-07",{"date":170,"type":43},{"date":198,"type":43},"2026-03-15",{"date":200,"type":23},"2026-08",{"name":202,"class":50},"Ankara Training and Research Hospital",{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":12,"sex":18,"minAge":210,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":24,"phases":214,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":230},"100486255","laparoscopic-single-anastomosis-sleeve-ileal-bypass-versus-laparoscopic-sleeve-gastrectomy-for-morbid-obesity-100486255","NCT05611697","Laparoscopic Single Anastomosis Sleeve Ileal Bypass Versus Laparoscopic Sleeve Gastrectomy for Morbid Obesity","Laparoscopic Single Anastomosis Sleeve Ileal Bypass Versus Laparoscopic Sleeve Gastrectomy for Morbid Obesity: A Randomized Trial","Inclusion Criteria:\n\n1. Morbid obesity at referral for bariatric surgery (i.e. a body-mass index \\[BMI\\] of ≥35 kg\u002Fm2 with obesity-related comorbid conditions or ≥40 kg\u002Fm2 with or without such comorbidities).\n2. Age 20-60 years.\n3. Previous failed attempts of weight loss.\n4. Norwegian speaking patients.\n\nExclusion Criteria:\n\n1. BMI ≥55 kg\u002Fm2.\n2. A history of major abdominal or bariatric surgery (excluding appendectomy, cholecystectomy, and sectio).\n3. Established disabling cardiopulmonary disease, ongoing treatment for cancer, long-term steroid use, and conditions believed to be associated with poor adherence after surgery.\n4. Previous or current gastroesophageal reflux symptoms with daily use of antireflux medication. Patients are also excluded if preoperative manometry identifies a hiatal hernia (≥4cm in axial length) or if preoperative upper endoscopy identifies esophagitis grade C or D (LA classification), peptic stricture, Barrett's esophagus, or esophageal carcinoma.\n5. Achalasia\n6. Pregnancy.","20 Years","60 Years",{"count":213,"type":23},220,[26],"This study will compare two bariatric surgical interventions in terms of weight loss, gastroesophageal reflux, and effects on obesity-related comorbid conditions in morbidly obese patients.",[30],[218,219,220],"procedure: sleeve gastrectomy","bariatric surgery","procedure: single anastomosis sleeve ileal bypass","2026-05-14",{"date":223,"type":43},"2026-05-18",{"date":225,"type":43},"2023-02-17",{"date":227,"type":23},"2031-12",{"name":229,"class":50},"Oslo University Hospital",2,{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":241,"conditions":242,"keywords":243,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":51},"100576125","periodontal-microbiota-of-patients-candidates-for-bariatric-surgery-with-body-mass-index-greater-than-30-100576125","NCT06781229","Periodontal Microbiota of Patients Candidates for Bariatric Surgery With Body Mass Index Greater Than 30","Non-interventional Study Exploring the Composition of the Periodontal Microbiota of Patients With Body Mass Index Greater Than 30 That Are Candidates for Bariatric Surgery","OROBESITE","Inclusion Criteria:\n\n* BMI greater than or equal to 30\n* Be on the list of patients scheduled for bariatric surgery,\n* Be able to receive information about the study and understand the information form in order to take part in the study. This implies mastering the French language,\n\nExclusion Criteria:\n\n* Alcohol consumption \\>30g\u002Fd (men) or 20g\u002Fd (women),\n* Having taken antibiotics, prebiotics or probiotics in the month prior to inclusion (this has an influence on the composition of the patient's microbiota),\n* During pregnancy or breastfeeding,\n* For whom oral surgery is planned (surgery for benign or malignant tumours of the maxillary and mandibular bone bases), or with a history of oral surgery in the month prior to inclusion,\n* At risk of infection (existence of one or more of the following known chronic infectious diseases: HIV, HBV, HCV and mononucleosis) and\u002For chronic renal insufficiency (creatinine clearance \\\u003C 60ml\u002Fmin),\n* Patients with a general pathology that contraindicates the performance of diagnostic procedures such as periodontal probing (patients at high risk of infective endocarditis according to the ANSM).\n* Totally edentulous patients",{"count":240,"type":23},170,"The goal of this observational study is to compare the microbiological composition of the periodontal plaque of obese people undergoing bariatric surgery according to their Body Mass Index. The main question it aims to answer is:\n\nDoes obese patients have different microbiote according to their obesity?\n\nObesity being classified in two groups :\n\n* group \"obesity\" for a BMI between 30 and 35\n* versus \"morbid obesity\" group with a BMIabove 35.\n\nParticipants who are scheduled to undergo bariatric surgery as part of their regular medical care will answer questions about their quality of life, hygiene habits, and saliva and periodontal samples will be taken.",[124,30],[244,245,246,247],"microbiological composition","obese","bypass","Body mass index","2026-05-07",{"date":250,"type":43},"2026-05-08",{"date":252,"type":43},"2025-02-03",{"date":254,"type":23},"2028-02-03",{"name":256,"class":50},"University Hospital, Toulouse",{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":93,"enrollmentInfo":264,"targetDuration":4,"studyType":24,"phases":266,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":283},"100431188","distal-gastric-bypass-outcome-in-revision-surgery-after-roux-en-y-gastric-bypass-100431188","NCT04894838","DIStal gastriC Bypass OUtcome in Revision SurgEry After Roux-en-y Gastric Bypass","DISCOURSE","Inclusion Criteria:\n\n* Age 18-65 years;\n* BMI ≥40 kg\u002Fm2 or BMI ≥35 kg\u002Fm2 with obesity related comorbidity;\n* Weight regain or insufficient weight loss (EWL\\\u003C50% or TWL\\\u003C20%)15,16 following RYGB;\n* Multidisciplinary team screening at one of the bariatric centres;\n* Informed consent and willing to enter the follow-up program.\n\nExclusion Criteria:\n\n* Failed Roux-en-Y gastric bypass due to anatomic, surgical reasons (gastric pouch dilatation \\>50 mL, gastro-gastric fistula, gastro-jejunostomy);\n* Distalisation of RYGB is technical infeasible (judgment by surgeon);\n* Inflammatory bowel disease, celiac disease, irritable bowel syndrome and other causes of chronic diarrhea;\n* Severe concomitant disease (such as carcinomas and neurodegenerative disorders);\n* Pregnant women;\n* Noncompliance in follow-up or unwilling to undergo surgery;\n* Inability of reading\u002Funderstanding and filling out questionnaires.",{"count":265,"type":23},150,[26],"This study is designed as a prospective multicenter randomized controlled clinical trial comparing two surgical techniques of distal gastric bypass (DGB) in revisional surgery following failed Roux-en-Y gastric bypass. Patients will be randomly allocated 1:1 to A) DGB with lengthening of the BPL (DGB type I) or B) DGB with extended AL (DGB type II). Randomisation is stratified for participating center. The study will be performed in a clinical and out-patient setting with regular visits at 1.5, 3, 6, 12, 18, 24 and 36 months post intervention. The study will be set up as a multicenter study with bariatric centers: St. Antonius hospital, Groene Hart hospital, OLVG, Rijnstate hospital, Elisabeth Twee-steden Hospital, Bravis hospital, Medisch Centrum Leeuwarden, Catharina Hospital.",[30,269],"Weight Gain",[29,271,272,273],"Weight regain","Failed RYGB","Distal gastric bypass","2026-04-24",{"date":276,"type":43},"2026-04-27",{"date":278,"type":43},"2021-05-01",{"date":280,"type":23},"2029-12",{"name":282,"class":50},"St. Antonius Hospital",8,{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":93,"enrollmentInfo":291,"targetDuration":4,"studyType":24,"phases":293,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":51},"100462718","phase-4-evaluation-of-propofol-dosing-based-on-total-body-weight-using-closes-loop-anaesthesia-delivery-system-100462718","NCT05305313","Evaluation of Propofol Dosing Based on Total Body Weight Using Closes-loop Anaesthesia Delivery System","Evaluation of Propofol Dosing Based on Total Body Weight Versus Adjusted Body Weight in Obese Patients Receiving Total Intravenous Anaesthesia With Automated Closed-Loop Anaesthesia Delivery System: A Randomized Controlled Study","Inclusion Criteria:\n\n1. ASA physical status II\u002FIII\n2. laparoscopic and non-laparoscopic surgery of more than 60-minutes duration\n3. Body mass index \\> 35kg\u002Fm2\n\nExclusion Criteria:\n\n1. Cardiovascular disorders (uncontrolled hypertension, Atrio-ventricular block, sinus bradycardia, congenital heart disease, reduced LV compliance \\& diastolic dysfunction)\n2. Neurological disorders (previous neurosurgery, psychiatric disorders, autonomic nervous system disorders- orthostatic hypotension, transient ischemic attacks)\n3. Hepato-renal insufficiency\n4. Uncontrolled diabetes mellitus\n5. Known allergy\u002Fhypersensitivity to study drug\n6. Pulmonary dysfunction (restrictive \u002Fobstructive lung disease)\n7. Acute\u002Fchronic drug dependence\u002Fsubstance abuse",{"count":292,"type":23},46,[294],"PHASE4","The pharmacokinetic profile of various drugs is altered in obese patients especially those administered by the intravenous route. Propofol is the commonly used intravenous anesthetic agent for induction and maintenance of anaesthesia as part of total intravenous anaesthesia (TIVA) regimen. A major concern with propofol dosing based on total body weight (TBW) in obese patients is disproportionate drug administration leading to undue drug accumulation in body with a potential to overdosing, delayed recovery from anaesthesia, and adverse hemodynamic outcome. Studies on propofol dosing based on various weight scalars have recommended that lean body weight (LBW) should be used for calculating bolus dose during anaesthesia induction and TBW or adjusted body weight (ABW) for arriving at an infusion dose required for maintenance of anesthesia. Although propofol delivery based on dose calculated by TBW has been well researched the evidence for propofol delivery based on dose calculated by ABW is lacking.\n\nRecent advance in the delivery of propofol has been the development of computer controlled anaesthesia delivery systems. These devices deliver propofol based on patient's frontal cortex electrical activity as determined by bispectral index (BIS). Evaluation of anaesthesia delivery by these systems has shown that they deliver propofol and maintain depth of anaesthesia with far more precision as compared to manual administration. One such indigenously developed computer controlled anaesthesia delivery system is the closed loop anesthesia delivery system (CLADS). CLADS functions on control of processed EEG response parameter captured from anesthetized patients with the help of a BIS- monitor, which is continuously fed into an automated drug infusion pump. The infusion pump then accordingly delivers the anesthetic drug to the patients based on pharmacodynamic requirements. The investigators plan to evaluate the propofol maintenance dose requirement based on TBW versus ABW using CLADS for propofol delivery.",[30,297,298],"Anesthesia","Propofol","2026-04-22",{"date":276,"type":43},{"date":302,"type":43},"2022-04-19",{"date":304,"type":23},"2027-11-10",{"name":306,"class":50},"Sir Ganga Ram Hospital",{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":24,"phases":315,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":330},"100525267","transpulmonary-pressure---guided-mechanical-ventilation-in-morbidly-obese-ards-patients-a-feasibility-study-100525267","NCT06119516","Transpulmonary Pressure - Guided Mechanical Ventilation in Morbidly Obese ARDS Patients: a Feasibility Study.","TGV-MOA","Inclusion Criteria:\n\n* Adult patient (aged 18 years or older)\n* Class III morbid obesity (BMI \\> 40 kg\u002Fm2)\n* Moderate or severe ARDS criteria (according to the Berlin definition)\n* Less than 72 hours between fulfilling moderate or severe ARDS criteria and inclusion\n* Tracheal intubation and invasive mechanical ventilation\n* Informed consent (patient, next of kin), with possibility of an emergency procedure with deferred consent\n* Covid-19 and non-Covid-19 patients\n\nExclusion Criteria:\n\n* Contra-indication to nasogastric tube (uncontrolled coagulopathy, severe thrombocytopenia, nasal trauma, esophageal varices)\n* Order to limit life-sustaining therapy\n* ExtraCorporal Membrane Oxygenation (ECMO) in use\n* Invasive mechanical ventilation \\> 96 hours\n* Elevated intracranial pressure\n* Active air-leak: pneumothorax, pneumomediastinum\n* Pregnancy or breast feeding\n* Patient on state medical aid",{"count":151,"type":23},[26],"The goal of this clinical trial is to test a personalized intervention aiming to optimize the mechanical ventilator settings in morbidly obese patients suffering from moderate to severe Acute Respiratory Distress Syndrome (ARDS). The intervention consists of personalized measurements and calculations of the different pressures inside the thorax. The main question to answer is:\n\n• Will the evaluated esophageal pressure-guided strategy lead to different mechanical ventilator settings than suggested by a strategy largely used in ARDS patients in France?\n\nA specific nasogastric probe permitting to measure esophageal pressure will monitor participants. Esophageal pressure will act as an indicator of the pleural pressure. Other respiratory signals displayed by the mechanical ventilators will also be acquired.\n\nFurther, ventilator settings will be adjusted to the evaluated esophageal pressure-guided strategy, with possible benefit of this personalized approach.",[318,30],"ARDS, Human",[318,320,188,321],"Obesity, morbid","Transpulmonary pressure",{"date":323,"type":43},"2026-04-21",{"date":325,"type":43},"2024-04-04",{"date":327,"type":23},"2027-07-04",{"name":329,"class":50},"Assistance Publique - Hôpitaux de Paris",5,{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":18,"minAge":339,"maxAge":93,"enrollmentInfo":340,"targetDuration":4,"studyType":24,"phases":342,"briefSummary":343,"conditions":344,"keywords":347,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":51},"100539878","metabolic-effects-of-a-diet-replaced-with-essential-amino-acids-100539878","NCT06309563","Metabolic Effects of a Diet Replaced With Essential Amino Acids","Study on the Metabolic Effects of a Diet Replaced With Essential Amino Acids and Carboxylic Acids (EAA-AC) in Patients With Severe Obesity","AMINOB","Inclusion Criteria:\n\n\\- Obesity (BMI \\>35kg\u002Fm2)\n\nExclusion Criteria:\n\n* Type 2 diabetes mellitus\n* Renal failure\n* Heart failure (New York Heart Association NYHA, class IV)\n* Liver cirrhosis\n* Neoplasms\n* Muscular or non-autonomic pathologies\n* Neurological-neurodegenerative pathologies\n* Cognitive decline\n* Non-menopausal women.\n* Patients who have undergone bariatric surgery in the previous 12 months\n* Patients on pharmacological treatment for weight loss in the last three weeks\n* Patients using vitamin and amino acid supplements in the last three weeks\n* Patients on hormone therapy (e.g. L-thyroxine, testosterone).","45 Years",{"count":341,"type":23},60,[26],"The effectiveness of low-protein diets supplemented with essential aminoacid (EAA) formulas in genetic disorders of amino acid (AA) catabolism, such as maple syrup urine disease (MSUD), is widely recognized (Blackburn PR et al. 2017). The main aim of the present study is to evaluate a difference in the effectiveness of a multidisciplinary rehabilitation program in patients with high degree of obesity with and without supplementation of this new formula of amino acids (essential + tricarboxylic acids - EAA-AC). For this reason, patients of both sexes, aged between 45 and 65, suffering from high-grade obesity will be recruited in Piancavallo. The enrolled patients divided, randomly, into two groups will be given: EAA-AC group a low-calorie and low-protein diet integrated with 4 sachets of EAA-AC supplement per day; the control group will follow a low-calorie and low-protein diet only with placebo. The parameters considered, after two weeks of treatment, will be: weight loss; the maintenance\u002Frecovery of muscle mass assessed through changes in body composition and functional tests (Hand grip, 6MWT or TUG) but also through the analysis of mitochondrial function in PBMC and circulating levels of mtDNA; the improvement of the glucose picture and the lipid profile.\n\n1 month after discharge, patients will carry out an outpatient check-up to evaluate the maintenance of muscle mass using impedance testing.",[345,346],"Obesity Morbid","Weight Loss",[348],"Muscle mass during weight loss","2026-03-26",{"date":351,"type":43},"2026-03-31",{"date":353,"type":43},"2023-08-30",{"date":355,"type":23},"2026-12-31",{"name":357,"class":50},"Istituto Auxologico Italiano",{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":93,"enrollmentInfo":364,"targetDuration":4,"studyType":24,"phases":366,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":51},"100352417","long-term-substantial-weight-loss-and-insulin-regulation-of-lipolysis-100352417","NCT03868592","Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis","Inclusion Criteria:\n\n* BMI 40 - 50 kg\u002Fm2.\n* Mo active physical illness that would interfere with mobility or weight loss after bariatric surgery\n\nExclusion Criteria:\n\n* Type 1 or Type 2 Diabetes diagnosis or fasting plasma glucose ≥126 mg\u002FdL\n* Active coronary artery disease\n* Participation in structured exercise (\\>2 times per week for 30 minutes or longer)\n* Smoking\n* Medications known to affect adipose tissue metabolism (e.g., beta blockers, corticosteroids)\n* Renal insufficiency (serum creatinine \\> 1.5mg\u002Fdl)\n* Chronic active liver disease (Bilirubin \\> 17mmol\u002FL, AST \\> 144 IU\u002FL, or ALT\\>165IU\u002FL)\n* Pregnancy or breastfeeding.",{"count":365,"type":23},30,[26],"It is not known how much improvement in insulin regulated lipolysis (the breakdown of triglycerides) occurs following substantial, sustained weight loss. Researchers will test the effects of inflammation and lipolysis regulation in people before and after bariatric surgery (sleeve gastrectomy) to answer these questions.",[30],"2026-02-27",{"date":371,"type":43},"2026-03-03",{"date":373,"type":43},"2019-08-01",{"date":375,"type":23},"2027-05",{"name":377,"class":50},"Mayo Clinic",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":386,"enrollmentInfo":387,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":388,"conditions":389,"keywords":393,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":51},"100493945","efficacy-and-safety-of-endoscopic-antral-myotomy-as-a-novel-weight-loss-procedure-100493945","NCT05711758","Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure","Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure: A Pilot Study","PSAM","Inclusion Criteria:\n\n* subjects must be 18-70 years of age\n* eligible for endoscopic and surgical weight loss procedures\n* body mass index (BMI) greater than 35 kg\u002Fm2\n* Individuals must be in excellent mental health\n* able to understand and sign informed consent\n* available to return for all routine follow-up study visits\n\nExclusion Criteria:\n\n* untreated H. pylori infection\n* gastroparesis\n* active smoking\n* an ongoing or a history of treatment with opioids in the last 12 months prior to enrollment\n* previous pyloromyotomy or pyloroplasty\n* gastrointestinal obstruction\n* severe coagulopathy\n* esophageal or gastric varices and\u002For portal hypertensive gastropathy\n* pregnancy or puerperium\n* any inflammatory disease of the gastrointestinal tract (including but not limited to severe (LA Grade C or D) esophagitis, active gastric ulceration, active duodenal ulceration, or specific inflammation such as Crohn's disease)\n* malignant or premalignant gastric diseases (such as high grade dysplasia, gastric cancer, or GIST)\n* severe cardiopulmonary disease or a history of coronary artery disease (including myocardial infarction within the past 6 months, poorly controlled hypertension, required use of NSAIDs)\n* lactation\n* history of gastrointestinal surgery\n* any serious health condition unrelated to their weight that would increase the risk of endoscopy\n* chronic abdominal pain\n* active psychological issues preventing participation in a lifestyle modification program\n* a known history of endocrine disorders affecting weight (uncontrolled hypothyroidism)\n* an inability to provide informed consent\n* use of any medication that may interfere with weight loss\n* use of any medication that may interfere with gastric emptying\n* any other condition which the investigator may deem as an impediment to compliance or hinder completion of the proposed study","70 Years",{"count":365,"type":23},"Gastric myotomy has been performed for several years as a means of addressing chronic stenosis after sleeve gastrectomy and treating gastroparesis. The Pylorus Sparing Antral Myotomy (PSAM) technique has the opposite effect by leaving the pylorus intact and extending the myotomy proximally to the distal gastric body. PSAM was initially combined with ESG and shown to delay gastric emptying and provide greater weight loss without impacting tolerability (GCSI score) or the safety profile of the procedure (2 DDW GEM abstracts). PSAM has not been evaluated alone, without concomitant ESG. Since delayed gastric emptying alone is known to promote weight loss, it is thought that PSAM alone (without ESG) may provide similar efficacy, while reducing procedure time and adverse events. There have been no clinical studies that investigate the efficacy of PSAM independent of ESG. This pilot study aims to address this lack of information by evaluating the safety, tolerability, and short-term efficacy of PSAM, in addition to exploring its impact on gastric physiology. This will also provide data that may be used in designing a larger clinical trial.",[29,30,390,391,392],"Obesity, Primary","Metabolic Disease","Delayed Gastric Emptying Following Procedure",[394,395,396,397,398,399,400,401,402,403,404],"Pylorus Sparing Antral Myotomy (PSAM)","Gastric physiology","Gastric emptying","Pylorus-sparing antral myotomy","Myotomy","Endoscopic Sleeve Gastroplasty (ESG)","TransPyloric Shuttle (TPS)","Intragastric balloon (IGB)","Endoscopic bariatric and metabolic therapies (EBMT)","Gut Hormones","Gastric Emptying Breath Test","2026-02-26",{"date":407,"type":43},"2026-03-02",{"date":409,"type":43},"2023-09-22",{"date":411,"type":23},"2027-12",{"name":49,"class":50},{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":420,"sex":18,"minAge":421,"maxAge":386,"enrollmentInfo":422,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":423,"conditions":424,"keywords":427,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":51},"100380359","investigating-the-link-between-type-2-immunity-and-nafld-in-human-obesity-100380359","NCT04232566","Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity","Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity- AIM 1","Inclusion Criteria:\n\n* Undergoing gastric bypass surgery\n* Confirmed AUROC F=0 or F\\>2 liver fibrosis\n* Age 30-70 years\n* BMI greater than 40 kg\u002Fm2\n* Negative pregnancy test (female only)\n* Lab Values: Normal TSH\n\nExclusion Criteria:\n\n* Autoimmune diseases\n* Hepatitis B or C positive\n* Heavy alcohol use\n* Active smoking history\n* Active cancer history\n* History of asthma\n* History of COPD\n* Taking Plavix or Coumadin\n* Blood donation within past 2 months\n* Glucocorticoid Therapy\n* Taking antihistamine on regular basis",true,"30 Years",{"count":341,"type":23},"This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how this affects its appearance and function and ultimately insulin resistance.",[30,425,426],"NASH - Nonalcoholic Steatohepatitis","Chronic Inflammation",[100,428,429,430],"nash","adipose tissue inflammation","insulin resistance","2026-01-26",{"date":433,"type":43},"2026-01-28",{"date":435,"type":43},"2022-02-20",{"date":437,"type":23},"2027-12-30",{"name":377,"class":50},{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":420,"sex":447,"minAge":19,"maxAge":448,"enrollmentInfo":449,"targetDuration":4,"studyType":24,"phases":450,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":51},"100552748","time-restricted-eating-among-pregnant-females-with-severe-obesity-100552748","NCT06477120","Time-restricted Eating Among Pregnant Females With Severe Obesity","A Pilot Study of Time-restricted Eating Among Pregnant Females With Severe Obesity","TRE-Preg","Inclusion criteria:\n\n* Female based on sex assigned at birth\n* Preconception body mass index (BMI) 35.0 - 60 kg\u002Fm2\n* Singleton pregnancy\n* Age 18-44 years old\n* 14 - \\\u003C = 20 weeks gestational age\n* Fluency in English to provide consent and complete study procedures\n* Ability to provide informed consent\n* Cleared by study doctor and the obstetrician\u002Fmid-wife provider to participate\n* Access to a smartphone to complete intervention procedures\n\nExclusion criteria:\n\n* Deemed medically high risk\n* Multiple pregnancy (e.g., twins)\n* Type 1 or 2 diabetes mellitus\n* Early gestational diabetes (diagnosed at \\\u003C = to17 weeks gestational age through an oral glucose tolerance test)\n* Currently eating ≤ 12 hours daily\n* Autoimmune disorder (e.g., rheumatoid arthritis)\n* iron deficiency anemia\n* Inflammatory bowel disease\n* Previous spontaneous preterm birth\n* History of bariatric surgery\n* Night shift work\n* Currently incarcerated\n* Eating disorder","FEMALE","44 Years",{"count":341,"type":23},[26],"In the United States, a body mass index (BMI) of at least 35.0 kg\u002Fm2 affects about 15% of women of reproductive age. Severe obesity is a significant predictor of adverse perinatal outcomes including gestational diabetes mellitus, pre-eclampsia, premature birth, and at its most severe, fetal death, birth defects and a three-fold greater risk of maternal mortality. Observational studies suggest weight maintenance and even modest body fat loss and altering the maternal metabolic milieu (availability of glucose and lipids) in the gestational period may be important to reducing perinatal health risks among pregnant females with severe obesity. The proposed research aims to assess time-restricted eating in the 2nd and 3rd trimesters of pregnancy to explore the effects on maternal weight, and perinatal health outcomes compared to standard clinical care.",[30,453,454],"Time Restricted Eating","Pregnancy Weight Gain","2026-01-22",{"date":457,"type":43},"2026-01-23",{"date":459,"type":43},"2024-09-09",{"date":461,"type":23},"2026-11-29",{"name":463,"class":50},"University of Illinois at Chicago",{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":468,"acronym":4,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":211,"enrollmentInfo":470,"targetDuration":4,"studyType":24,"phases":472,"briefSummary":473,"conditions":474,"keywords":475,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":51},"100457916","management-of-sleeve-gastrectomy-failure-using-single-anastomosis-metabolic-surgery-100457916","NCT05242835","Management of Sleeve Gastrectomy Failure Using Single-anastomosis Metabolic Surgery","Inclusion Criteria:\n\n* had sleeve gastrectomy a minimum of 18 months before\n* still meet the NIH criteria for bariatric surgery (BMI≥35kg\u002Fm2 with major comorbidities or BMI≥40kg\u002Fm2) or patients with EWL\\\u003C50% or significant weight regain (≥20%EWL)\n\nExclusion Criteria:\n\n* general contra-indication for bariatric surgery\n* BMI\\\u003C35kg\u002Fm2\n* pregnancy\n* cirrhosis\n* abnormal bowel habits including irritable bowel syndrome and inflammatory bowel disease",{"count":471,"type":23},151,[26],"Sleeve gastrectomy (SG) has become the most commonly performed weight loss surgery, accounting for 60% of all bariatric operations worldwide. While technically easier with less side-effects and nutritional risks than other operations, SG is also associated with a higher risk of failure (20 to 40%). In such case, the most effective option consists in adding an intestinal bypass called the Biliopancreatic Diversion with Duodenal Switch (BPD-DS). This surgery is, however, technically challenging and yields a significant risk of complications, nutritional deficiencies or gastro-intestinal side-effects. Recently, a simplified version of the Standard DS, called Single-Anastomosis Duodenoileal Switch (SADI-S) was endorsed by surgical societies as one of the approved bariatric procedures. There is currently no prospective or randomized data to support the effectiveness of this new procedure, especially as a revisional approach. The Overall Objective of this randomized controlled trial project is to establish the clinical benefits of the SADI-S as a revisional surgery after SG, while also considering critical issues related to sex and gender. The investigator Overall Hypothesis is that the SADI-S represents a relevant revisional option for weight loss and metabolic recovery in women and men suffering from severe obesity who had a previous SG. The investigator propose to address the following research question.\n\nResearch Question: What are the clinical effects of SADI-S compared to standard DS when used as a revisional procedure after SG, in patients with obesity? Participants who need revisional surgery after SG will be enrolled in a prospective, randomized, double-blind (patient-evaluator), non-inferiority trial comparing SADI-S vs DS. The primary outcome will be 12-month excess weight loss. Secondary outcomes will be perioperative complications, risk of malnutrition, quality of life and gastrointestinal side effects. The investigator hypothesize that SADI-S offers similar weight loss compared to standard DS, but a lower risk of complications and nutritional deficiencies.\n\nWith the increase in the number of bariatric operations performed worldwide and the recent endorsement of the SADI-S as a regular procedure, reliable clinical data are urgently needed. The present proposal will directly address this knowledge gap.",[29,30],[194],"2025-12-01",{"date":478,"type":43},"2025-12-08",{"date":480,"type":43},"2023-02-03",{"date":482,"type":23},"2027-03",{"name":484,"class":50},"Laval University",{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":93,"enrollmentInfo":492,"targetDuration":4,"studyType":24,"phases":494,"briefSummary":495,"conditions":496,"keywords":498,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":51},"100539115","endoscopic-sleeve-gastroplasty-technique-comparison-for-weight-loss-100539115","NCT06299644","Endoscopic Sleeve Gastroplasty Technique Comparison for Weight Loss","Endoscopic Sleeve Gastroplasty Technique Comparison for Weight Loss Using the Endomina Plicating Device: A Randomized Trial","Inclusion Criteria:\n\n1. Patients with 18-65 years of age\n2. BMI ≥ 30 kg\u002Fm2\n3. Capable of giving informed consent and available to return for follow-up visit\n\nExclusion Criteria:\n\n1. Untreated H. pylori infection\n2. Active gastric or duodenal ulceration\n3. Malignant or premalignant gastric diseases (such as intestinal metaplasia, high grade dysplasia, gastric adenocarcinoma, or gastrointestinal stromal tumor (GIST))\n4. Severe reflux esophagitis (Los Angeles Classification (LA) Grade C or D)\n5. Esophageal or gastric varices and\u002For portal hypertensive gastropathy\n6. Gastroparesis\n7. History of gastric surgery\u002Fendoscopic procedure\n8. Active psychological issues preventing participation in a lifestyle modification program\n9. Known history of endocrine disorders affecting weight (uncontrolled hypothyroidism)\n10. Severe coagulopathy\n11. Active smoking\n12. Substance abuse\n13. Serious health condition that increased risk of anesthesia and\u002For endoscopic procedure\n14. Pregnancy or lactation\n15. Patients who require Non-Steroidal Anti-inflammatory Drugs (NSAID) use",{"count":493,"type":23},10,[26],"The Investigators propose suture plication placement at the distal gastric body drives a significant portion of weight loss in endoscopic sleeve and sutures only need to be placed in the distal gastric body. Therefore, in this pilot study, the investigators aim to compare \"belt\" with \"belt and suspenders\" plication pattern using the Endomina system to determine percent total weight loss.",[29,30,391,497],"Weight, Body",[499,500,396,501,502,346,503,504,505,506],"Endoscopic Bariatric and Metabolic Therapies (EBMT)","Endoscopic Bariatric Therapies (EBT)","Endoscopic Suturing","endoscopic sleeve gastroplasty (ESG)","Bariatric Endoscopy","Weight Management","Endoscopic plication","Gastric plication","2025-11-25",{"date":509,"type":43},"2025-12-02",{"date":511,"type":23},"2026-09",{"date":513,"type":23},"2028-05",{"name":515,"class":50},"Brigham and Women's Hospital",{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":523,"targetDuration":4,"studyType":24,"phases":525,"briefSummary":526,"conditions":527,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":330},"100509833","postextubation-use-of-noninvasive-respiratory-support-in-severely-obese-patients-100509833","NCT05918575","Postextubation Use of Noninvasive Respiratory Support in Severely Obese Patients","A Randomized Controlled Trial of Postextubation Use of Noninvasive Respiratory Support in Severely Obese Patients","Inclusion Criteria:\n\n1. Adult, age ≥ 18 years old\n2. Receiving invasive mechanical ventilation for ≥24 hours\n3. BMI ≥40 kg\u002Fm2\n4. Undergoing planned extubation per treating team\n5. Arterial pH ≥7.35 or venous pH ≥ 7.31 within 30 mins of spontaneous breathing trial (SBT)\n\nExclusion Criteria:\n\n1. Pregnant\n2. Use of extra-corporeal membrane oxygenation\n3. Chronic tracheostomy in place\n4. Unplanned or accidental extubation\n5. Terminal\u002Fcompassionate extubation\n6. Contraindication to NIV use\n7. Intubated because of an acute exacerbation of COPD\n8. Underlying neuromuscular disease\n9. No reintubation requested by patient\u002Ffamily\n10. Documented\u002Fknown history of chronic hypercapnic respiratory failure on home NIV (including bilevel PAP).\n11. Enrolled in any other outcome study\n12. Treating clinician feels that HFNC or NIV are either mandatory or contraindicated for a given patient",{"count":524,"type":23},250,[26],"Around 20% of the obese patients with higher body mass index (BMI) who are taken off the breathing tube and breathing machine (ventilator) end up needing it back to support breathing. The re-application of breathing tube is associated with poor outcomes, including high risk of pneumonia, longer hospital stays, and death. The purpose of this study is to assess if prophylactic use of noninvasive breathing support after removing the breathing tube lowers the chance of needing the breathing tube again.",[30,528],"Extubation Failure","2025-10-16",{"date":531,"type":43},"2025-10-20",{"date":533,"type":43},"2023-07-10",{"date":535,"type":23},"2026-12-01",{"name":537,"class":50},"Rush University Medical Center",{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":93,"enrollmentInfo":546,"targetDuration":4,"studyType":24,"phases":547,"briefSummary":548,"conditions":549,"keywords":550,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":51},"100499028","bariatric-surgery-and-modulation-of-perceived-satiety-100499028","NCT05777928","Bariatric Surgery and Modulation of Perceived Satiety","Sleeve Gastrectomy and OverStitch™ Endoscopic Suturing System in the Modulation of Perceived Satiety","BAR_SAZ","Inclusion Criteria:\n\n* subjects who are eligible for sleeve gastrectomy according to the SICOB criteria\n* subjects, previously undergoing Sleeve Gastrectomy or gastric bypass, who, for weight regain, have been scheduled for revision surgery with the OverStitch™ Endoscopic Suturing System\n\nExclusion Criteria:\n\n* none",{"count":341,"type":23},[26],"Bariatric surgery is the ideal therapeutic strategy for patients with severe obesity when lifestyle interventions have failed. Unfortunately, weight recovery after surgery affects one third of patients and is due to several factors, such as recovery of incorrect eating behaviour, reduction of physical activity or hormonal factors. Dilation of gastro-jejunal anastomosis is one of the main causes as it determines reduction of satiety in the patient and consequent increase of the portions of food consumed. In these cases it is necessary to make a review of gastro-jejunal anastomosis and to reduce surgical complications in recent years has been developed a method that allows the execution of sutures through a totally endoscopic way (OverStitch™ Endoscopic Suturing System).\n\nLiterature studies to assess hunger-satiety in patients undergoing bariatric surgery, suggest that surgery results in weight loss due to a series of changes in gastrointestinal physiology which impact on the feeling of hunger-satiety, and on the modification of the secretion of hormones involved in the regulation of gastric emptying such as the reduction of ghrelin secretion and the increase in postprandial cholecystokinin and GLP-1. There are no data in the literature on satiety in patients in previous bariatric surgery with weight recovery secondary to dilation of the gastro-jejunal anastomosis.\n\nThere are various methods to assess satiety, most of which are invasive and difficult to perform in routine clinical settings. A recently proposed method to evaluate the perception of satiety and validated on healthy adults, is the Water Load Tests (WLTs). The test consists in making the subject drink a quantity of water until he feels \"pleasantly\" full. The volume of water ingested is a valid indicator of the subjective feeling of satiety.\n\nThe aim of yhe study is to assess perceived satiety (measured by Water Load Test) after intervention of Sleeve Gastrectomy or a revision surgery with OverStitch™ Endoscopic Suturing System in obese individuals suitable for bariatric surgery",[30],[551],"obesity, satiety, Sleeve gastrectomy ,OverStitch","2025-09-30",{"date":554,"type":43},"2025-10-03",{"date":556,"type":43},"2021-06-03",{"date":558,"type":23},"2025-12-31",{"name":357,"class":50},{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":93,"enrollmentInfo":567,"targetDuration":4,"studyType":24,"phases":569,"briefSummary":570,"conditions":571,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":51},"100563776","phase-4-improving-efficacity-of-sleeve-gastrectomy-with-naltrexonebupropion-extended-release-tablet-100563776","NCT06620562","Improving Efficacity of Sleeve Gastrectomy With Naltrexone\u002FBupropion Extended-release Tablet","Improving Efficacity of Sleeve Gastrectomy With Naltrexone\u002FBupropion Extended-release Tablet - A Randomized Controlled Trial","Inclusion Criteria:\n\n* MBI above 30 kg\u002Fm2 with obesity-related comorbidity or above 35 kg\u002Fm2 without associated comorbidities.\n\nExclusion Criteria:\n\n* Revisional or reoperative surgery\n* Pregnancy or planned pregnancy in the next 24 months\n* Simultaneous use of other weight loss medication\n* Uncontrolled hypertension\n* Chronic opioid use or opiate agonist (e.g., methadone) or partial agonists (e.g., buprenorphine) use, or acute opiate withdrawal.\n* Use of other bupropion-containing products\n* Concomitant administration of monoamine oxidase inhibitors.\n* End-stage liver or kidney disease\n* Concomitant use of CYP2B6 inhibitors (ticlopidine or clopidogrel)\n* Concomitant administration of the antipsychotic thioridazine\n* Seizure disorder or a history of seizures\n* Cardiac pacemaker\n* Current or prior diagnosis of bulimia or anorexia nervosa",{"count":568,"type":23},108,[294],"The goal of this clinical trial is to assess the impact of combination therapy with Naltrexone-Bupropion (NB) in the post-operative period of sleeve gastrectomy (SG). on a) weight loss, b) resolution of comorbidities and c) eating behaviors.\n\nResearchers will compare SG-NB group with SG-placebo group to see if they experience significantly higher excess weight loss (EWL) at 12 and 24 months and if there is a significantly higher percentage of patients with an EWL above 50% in the SG-NB group versus in the SG-placebo group.\n\nParticipants will be randomized 1:1 to SG in combination with NB versus SG with placebo. Patients will be started one month after surgery on a progressive dose of Naltrexone\u002FBupropion extended-release or placebo. Duration of therapy will be 24 months.Both groups will benefit from behavioral and nutritional support.",[572,30],"Obesity; Drug","2025-08-04",{"date":575,"type":43},"2025-08-08",{"date":577,"type":43},"2025-06-04",{"date":579,"type":23},"2028-08",{"name":484,"class":50},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":211,"enrollmentInfo":587,"targetDuration":4,"studyType":24,"phases":589,"briefSummary":590,"conditions":591,"keywords":593,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":51},"100600537","phase-4-role-of-tranexamic-acid-in-reducing-hemorrhagic-events-in-bariatric-surgery-100600537","NCT07098780","Role of Tranexamic Acid in Reducing Hemorrhagic Events in Bariatric Surgery","Inclusion Criteria:\n\n* Patients above 18 years of age AND\n* Undergoing Laparoscopic Sleeve Gastrectomy and MGB\n* Morbid obesity\n\nExclusion Criteria:\n\n* Patients on anti-platelets\u002Fanti-coagulants\n* Patients with inherited or acquired bleeding disorders\n* Patients with any acute medical condition predisposing to bleeding\n* Hormonal contraceptives\n* Known Allery to TXA\n* Female hormonal replacement therapy",{"count":588,"type":23},140,[294],"The goal of this clinical trial is to learn if tranexamic acid (TXA) helps reduce bleeding during bariatric surgery, such as laparoscopic sleeve gastrectomy (LSG) and mini gastric bypass (MGB). It will also look at how safe TXA is for people undergoing these procedures. The main questions it aims to answer are:\n\nDoes TXA reduce the amount of blood loss during bariatric surgery? Are there any side effects or complications in patients who receive TXA? Researchers will compare TXA to standard care (no TXA) to see if it is effective in reducing bleeding.\n\nParticipants will:\n\nReceive either TXA or no TXA (placebo) before surgery Undergo standard bariatric surgery (LSG or MGB) Have their blood loss, hemoglobin levels, and any complications monitored during and after surgery",[592,124,30],"Hemorrhage",[194,594,595,596,597],"Tranexamic Acid","Hemorrhage in bariatric surgery","RCT","Randomised controlled trial","2025-07-29",{"date":600,"type":43},"2025-08-01",{"date":602,"type":43},"2023-06-12",{"date":604,"type":23},"2025-08-31",{"name":606,"class":50},"Patel Hospital, Pakistan",{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":386,"enrollmentInfo":614,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":616,"conditions":617,"keywords":618,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":51},"100327083","bariatric-surgery-and-pharmacokinetics-of-paracetamol-100327083","NCT03538457","Bariatric Surgery and Pharmacokinetics of Paracetamol","Bariatric Surgery and Pharmacokinetics of Paracetamol: BAR-MEDS Paracetamol","Inclusion Criteria:\n\n* Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway\n* Being a Norwegian citizen\n\nExclusion Criteria:\n\n* Having previously undergone resections in the GI-tract",{"count":615,"type":23},12,"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on paracetamol are investigated.",[30],[194,619,620,621,622],"Gastrointestinal tract","Biological availability","Pharmacokinetics","Acetaminophen","2025-06-05",{"date":625,"type":43},"2025-06-06",{"date":627,"type":43},"2016-11-02",{"date":629,"type":23},"2026-10",{"name":631,"class":50},"Norwegian University of Science and Technology",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":386,"enrollmentInfo":638,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":639,"conditions":640,"keywords":641,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":643,"startDateStruct":644,"completionDateStruct":645,"leadSponsor":646,"locationsCount":51},"100326846","bariatric-surgery-and-pharmacokinetics-of-valsartan-100326846","NCT03535376","Bariatric Surgery and Pharmacokinetics of Valsartan","Bariatric Surgery and Pharmacokinetics of Valsartan: BAR-MEDS Valsartan",{"count":615,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on valsartan are investigated.",[30],[194,619,620,621,642],"Valsartan",{"date":625,"type":43},{"date":627,"type":43},{"date":629,"type":23},{"name":631,"class":50},{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":386,"enrollmentInfo":653,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":654,"conditions":655,"keywords":656,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":661,"leadSponsor":662,"locationsCount":51},"100326625","bariatric-surgery-and-pharmacokinetics-of-venlafaxine-100326625","NCT03532477","Bariatric Surgery and Pharmacokinetics of Venlafaxine","Bariatric Surgery and Pharmacokinetics of Venlafaxine: BAR-MEDS Venlafaxine",{"count":615,"type":23},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on venlafaxine are investigated.",[30],[194,619,620,621,657],"Venlafaxine Hydrochloride",{"date":659,"type":43},"2025-06-10",{"date":627,"type":43},{"date":629,"type":23},{"name":631,"class":50}]